Clinical trial
Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell…
NCT00003182 · Hope Cancer Institute, Inc., Industry · Unknown status
Key facts
| NCT number | NCT00003182 |
|---|---|
| Title | Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck |
| Official title | A Phase I/II Study Using Cisplatin and Gemcitabine (Gemzar) for Advanced Head and Neck Cancer (Squamous Cell Carcinoma) |
| Lead sponsor | Hope Cancer Institute, Inc., Industry |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug |
| Interventions | cisplatin, gemcitabine hydrochloride |
| Enrollment | 40 |
| Start date | Mar 1, 1997 |
| First posted | Aug 2, 2004 |
| Last update posted | Dec 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: